Renflexis fda approval date?

See the DrugPatentWatch profile for Renflexis

What was Renflexis’s FDA approval date?

Renflexis (infliximab-abda), a biosimilar to Remicade, received FDA approval on September 24, 2016 [1].

When did Renflexis start being marketed?

FDA approval is the point the product is authorized for use in the U.S.; that same approval date (September 24, 2016) is the key timestamp associated with when Renflexis became available for prescribing and dispensing following authorization [1].

What is Renflexis approved for?

Renflexis is an infliximab-abda biosimilar indicated for multiple inflammatory conditions, including rheumatoid arthritis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis, and psoriatic arthritis (as reflected in FDA labeling associated with its approval) [1].

Sources:
[1] https://www.drugpatentwatch.com/p/renflexis-fda-approval-date